Abstract
A 75-year-old woman notes increasing difficulty with reading and walking down steps in dim light over the past 6 months. During her last comprehensive eye examination 1 year ago, she recalls that she had been diagnosed with early cataracts and also was told she had the beginning signs of macular degeneration. While she was somewhat anxious with this latter diagnosis, her doctor told her to consider taking a dietary supplement. She bought a multivitamin with lutein over the counter as she heard from a friend that people with macular degeneration should take this supplement. She believed that her progressive difficulty with vision was either because her glasses needed changing or her cataracts were worsening, or she was just losing vision with age.
Adapted in part from Clinical Advances in Age-Related Macular Degeneration, Johns Hopkins University School of Medicine Continuing Medical Education Enduring Material, 2007–2008.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1901.
The Age-Related Eye Disease Study Research Group. Potential public health impact of AREDS results: AREDS Report No. 11. Arch Ophthalmol. 2003;121:1621–1624.
Rosenfeld PJ, Brown DM, Heier JS, et al. for the MARINA study group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
Brown DM, Kaiser PK, Michels M, et al. Schneider S for the ANCHOR study group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1432–1444.
The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436.
Charkoudian LD, Gower EW, Solomon SD, Schachat AP, Bressler NB, Bressler SB. Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology. 2008;115(6):1032–1038.e4.
Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the age-related eye disease study (AREDS) AREDS Report No. 19. Ophthalmology. 2005;112:533–539.
The Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration. AREDS Report No. 18. Arch Ophthalmol. 2005;123:1570–1574.
American Academy of Ophthalmology. Age-Related Macular Degeneration: Medical Therapy and Surgery. Preferred Practice Pattern. San Francisco; American Academy of Ophthalmology, 2006. Available at aao.org/ppp.
Jampol LM. Bevacizumab vs ranibizumab treatment for age-related macular degeneration: A head-to-head comparison is needed. Arch Ophthalmol. 2007;125:557–558.
Chang TS, Bressler NM, Fine JT, Dolan CM, Ward HM, Klesert TR. For the MARINA study group: Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol. 2007;125(11):1460–1469.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bressler, N.M. (2009). Age-Related Macular Degeneration and Its Management. In: Lee, A.G., Beaver, H. (eds) Geriatric Ophthalmology. Springer, New York, NY. https://doi.org/10.1007/b137372_6
Download citation
DOI: https://doi.org/10.1007/b137372_6
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0009-8
Online ISBN: 978-1-4419-0014-2
eBook Packages: MedicineMedicine (R0)